Navigation Links
MIT: Removable 'cloak' for nanoparticles helps them target tumors
Date:5/3/2011

CAMBRIDGE, Mass. -- MIT chemical engineers have designed a new type of drug-delivery nanoparticle that exploits a trait shared by almost all tumors: They are more acidic than healthy tissues.

Such particles could target nearly any type of tumor, and can be designed to carry virtually any type of drug, says Paula Hammond, a member of the David H. Koch Institute for Integrative Cancer Research at MIT and senior author of a paper describing the particles in the journal ACS Nano.

Like most other drug-delivering nanoparticles, the new MIT particles are cloaked in a polymer layer that protects them from being degraded by the bloodstream. However, the MIT team, including lead author and postdoctoral associate Zhiyong Poon, designed this outer layer to fall off after entering the slightly more acidic environment near a tumor. That reveals another layer that is able to penetrate individual tumor cells.

In the ACS Nano paper, which went online April 23, the researchers reported that, in mice, their particles can survive in the bloodstream for up to 24 hours, accumulate at tumor sites and enter tumor cells.

The new MIT approach differs from that taken by most nanoparticle designers. Typically, researchers try to target their particles to a tumor by decorating them with molecules that bind specifically to proteins found on the surface of cancer cells. The problem with that strategy is that it's difficult to find the right target a molecule found on all of the cancer cells in a particular tumor, but not on healthy cells. Also, a target that works for one type of cancer might not work for another.

Hammond and her colleagues decided to take advantage of tumor acidity, which is a byproduct of its revved-up metabolism. Tumor cells grow and divide much more rapidly than normal cells, and that metabolic activity uses up a lot of oxygen, which increases acidity. As the tumor grows, the tissue becomes more and more acidic.

To build their targeted particles, the researchers used a technique called "layer-by-layer assembly." This means each layer can be tailored to perform a specific function.

When the outer layer (made of polyethylene glycol, or PEG) breaks down in the tumor's acidic environment, a positively charged middle layer is revealed. That positive charge helps to overcome another obstacle to nanoparticle drug delivery: Once the particles reach a tumor, it's difficult to get them to enter the cells. Particles with a positive charge can penetrate the negatively charged cell membrane, but such particles can't be injected into the body without a "cloak" of some kind because they would also destroy healthy tissues.

The nanoparticles' innermost layer can be a polymer that carries a cancer drug, or a quantum dot that could be used for imaging, or virtually anything else that the designer might want to deliver, says Hammond, who is the Bayer Professor of Chemical Engineering at MIT.

Other researchers have tried to design nanoparticles that take advantage of tumors' acidity, but Hammond's particles are the first that have been successfully tested in living animals.

The researchers are planning to further develop these particles and test their ability to deliver drugs in animals. Hammond says she expects it could take five to 10 years of development before human clinical trials could begin.

Hammond's team is also working on nanoparticles that can carry multiple payloads. For example, the outer PEG layer might carry a drug or a gene that would "prime" the tumor cells to be susceptible to another drug carried in the particle's core.


'/>"/>

Contact: Caroline McCall
cmccall5@mit.edu
Massachusetts Institute of Technology
Source:Eurekalert

Related biology news :

1. All wrapped up: K-State researchers graphene cloak protects bacteria, leading to better images
2. Moths cloaked in color
3. Invisibility cloak could protect against earthquakes
4. Common nanoparticles found to be highly toxic to Arctic ecosystem
5. Nanoparticles offer hope for common skin allergy
6. Rice scientist recognized for stellar work on nanoparticles, cell membranes
7. Growth-factor-containing nanoparticles accelerate healing of chronic wounds
8. With chemical modification, stable RNA nanoparticles go 3-D
9. Cinnamon can replace harmful chemicals used to create nanoparticles
10. Drugs encased in nanoparticles travel to tumors on the surface of immune-system cells
11. Probing the nanoparticle: Predicting how nanoparticles will react in the human body
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... 24, 2017 Biopharm Reports has carried ... use of nuclear magnetic resonance spectroscopy (NMR). This ... profiled current practices, developments, trends and end-user plans ... growth and opportunities. These areas include growth in ... needs and innovation requirements, hyphenated NMR techniques, main ...
(Date:1/21/2017)... 2017 Research and Markets has announced the ... report to their offering. ... The global voice recognition biometrics market to grow at ... The report covers the present scenario and the growth prospects of ... market size, the report considers the revenue generated from the sales ...
(Date:1/18/2017)... ROCKVILLE, Md. , Jan. 18, 2017  In ... with respect to mergers and acquisitions (M&A), and Kalorama ... reasons for such acquisitions have been shifting. Generally, uncertainty ... and the U.S. has changed the acquisitions ... situation has resulted in companies buying partners outside of ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... 2017 Origin (Origin Agritech, LLC, a subsidiary of Origin ... and Arcadia (Arcadia Biosciences, Inc., NASDAQ: RKDA), ... agricultural productivity traits and nutritional products, today announced their collaboration to ... in China to the United ... ...
(Date:2/22/2017)... ... February 22, 2017 , ... NDA ... PhD, MD former Acting Deputy Director in the FDA CDRH Division of Cardiovascular, ... has joined the company as an Expert Consultant. , In Dr. Spyker’s accomplished ...
(Date:2/22/2017)... and SAN DIEGO ... Holdings (the "Company") (OTCQB:CELZ) announced today expansion of ... donor stem cell product through establishment of laboratory ... research activities at the San Diego BioLabs facility, ... Boehringer Ingelheim, Novartis, and Sanofi. In ...
(Date:2/21/2017)... Md. , Feb. 21, 2017 Synthetic Biologics, ... designed to preserve the microbiome to protect and restore the health ... the year ended December 31, 2016 on Thursday, March 2, 2017, ... p.m. EST. The dial-in information for the call is as follows: ... ...
Breaking Biology Technology: